Evaluation of Serum HE4 in Ovarian Tumors, Its Comparison with Serum CA125 and Correlation with Histological Subtypes
Ovarian cancer is the seventh most common cancer in women and second most common female genital cancer in India. The high mortality is due to the fact that ovarian cancer is detected in later stages because of its non-specific symptoms like bloating, pain and increased size, gastrointestinal symptoms like indigestion, constipation or nausea with pelvic symptoms like bleeding. Cancer antigen 125 (CA125) has been useful for detection of ovarian cancer and also for follow-up. Recently, another tumor marker for ovarian cancer has been proposed, the Human Epididymis 4 protein (HE4), frequently over-expressed in ovarian cancers, especially in serous and endometrioid histology.
Materials and Methods
Descriptive study on 64 patients was done over a period of 1 year using pre- and postoperative serum samples for CA125 and HE4 and comparing them with histological diagnosis. ELISA for HE4 (Quantikine® Human HE4/WFDC2 Immunoassay) and chemiluminescence (ARCHITECT CA125 II assay) were used to assess CA125 levels and in serum. Results were compared between the two tumor markers, and statistical analysis (SPSS package Windows version 15.0) was done to compare the results.
Results and Conclusion
CA125 and HE4 levels were increased in malignant cases more than in benign cases. HE4 was seen as more specific than CA125, but, however, it did not prove superior in sensitivity. Hence, we conclude that CA125 along with HE4 will prove both as sensitive and as specific markers and hence prevent benign lesions being over-diagnosed and operated unnecessarily.
KeywordsOvarian lesions Tumor markers Serum HE4
Compliance with Ethical Standards
Conflict of interest
- 1.WHO. Cancer country profile of India. Geneva: WHO; 2014.Google Scholar
- 2.Dikshit RA (2012) Cancer Statistics in Indian women. Times of India, October 21, 2012 Google Scholar
- 6.Gajjar K, Ogden G, Mujahid MI, Razvi K. Symptoms and risk factors of ovarian cancer: a survey in primary care. ISRN Obstet Gynecol 2012; Article ID 754197, 6 pages.Google Scholar
- 7.Murthy NS, Shlini S, Suman G, Pruthvish S, Mathew A. Changing trends in incidence of ovarian cancer the Indian Scenario. Asian Pac J Cancer Prev. 2009;10:1025–30.Google Scholar
- 9.van Nagell JR. Ovarian cancer screening with annual transvaginal sonography: findings of 25,000 women screened. Int J Womens Health. 2014;6:25–33.Google Scholar
- 10.European Group on Tumour Markers. Tumour markers in gynaecological cancers—EGTM recommendations. Anticancer Res. 1999;19:2807–10.Google Scholar
- 16.Van Dalen A, Favier J, Hallensleben E, Burges A, Stieber P, de Bruijn HW, et al. Significance of serum CA 125 and TPS antigen levels for determination of overall survival after three chemotherapy courses in ovarian cancer patients during long-term follow-up. Eur J Gynaecol Oncol. 2009;30:609–15.Google Scholar
- 18.Molina R, Filella X, Bruix J, Mengual P, Bosch J, Calvet X, et al. Cancer antigen 125 in serum and ascitic fluid of patients with liver diseases. Clin Chem. 1991;37:1379–83.Google Scholar
- 20.Hellstrom I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003;63:3695–700.Google Scholar
- 28.Abdel-Azeez HA, Labib HA, et al. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses. Asian Pac J Cancer Prev. 2010;11:111–6.Google Scholar